Engineered Bacterial Therapy Activates Immune Response in Cancer Preclinical Studies
October 8, 2025
“ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.” BUFFALO, NY - October 8, 2025 – A new research paper was published… read more